vatalanib has been researched along with Rheumatoid Arthritis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aono, H; Ban, M; Honda, T; Inaba, T; Inoue, K; Kawashima, K; Okamoto, K; Sasabuchi, Y; Tajima, H; Takeno, Y; Tonouchi, A; Tsuboi, T; Yamamoto, M | 1 |
| Dawson, J; Esser, R; Grosios, K; Raychaudhuri, A; Wood, J | 1 |
2 other study(ies) available for vatalanib and Rheumatoid Arthritis
| Article | Year |
|---|---|
Pyridylmethylthio derivatives as VEGF inhibitors: part 2.
Topics: Angiogenesis Inhibitors; Animals; Arthritis, Rheumatoid; Cells, Cultured; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Mice; Neoplasms; Neovascularization, Pathologic; Pyridines; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2011 |
Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis.
Topics: Angiogenesis Inhibitors; Animals; Arthritis, Rheumatoid; Collagen; Female; Hyperalgesia; Male; Mice; Mice, Inbred DBA; Phthalazines; Pyridines; Rats; Receptors, Vascular Endothelial Growth Factor | 2004 |